Acquired ptosis (low-lying lids) is a common condition that affects adults of all ages, but occurs more often with increased age. It usually occurs when the muscles in the eyelid stretch and weaken, causing the lid to droop. However, it may be caused by other issues, such as cataract surgery, contact lens wear, or an underlying medical condition. Allen Smith, OD, and Nicole Gdowski, OD, of Lifetime Eyecare in Jenison, Michigan, are experienced in diagnosing and treating the symptoms of acquired ptosis. To protect your vision, it is important to have regular yearly eye exams. Get an eye exam today by calling or requesting an appointment online.request an appointment
UPNEEQ is the only FDA-approved prescription eyedrop for acquired ptosis (low-lying lids) that lifts your upper eyelids to open your eyes. We are currently running a promotion where when you buy two months we will give you the third month free- which puts our pricing below almost anyone else over the counter.
Acquired ptosis can lead to vision impairment
- Low-lying eyelid(s) can affect eyesight by not only blocking your vision, but also by reducing field of vision, which may interfere with day-to-day functions such as:
- Computer use
- Looking up without the need to tilt your head back
Millions of people over the age of 40 may have acquired ptosis and may not even be aware of it.
Only 15% have been diagnosed, and even fewer have received any treatment*
Upneeq Lifts The Eyelid(s) Quickly
- Most patients in clinical trials had a lift in their eyelids in as little as 2 hours
- 84% of patients had some level of improvement
- 74% of patients had more than a 50% improvement
- In one study, some patients saw a lift in their eyelids as fast as 5 minutes after the first dose
In clinical trials, Upneeq was proven to be safe and effective when used as directed. Common side effects (seen in 1-5% of patients) included eye inflammation, eye redness, dry eye, blurred vision, instillation site pain, eye irritation, and headache.
*Estimate of prevalence was calculated using both U.S. Census data and a published study by Sridharan et al. (1995). The Sridharan study observed a prevalence rate of 11.5% (n=400), which was then applied to the US Census’ projected 2020 population of Americans aged 50+ years.
WARNINGS AND PRECAUTIONS
Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.
Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.
Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.
More information please see Upneeq’s website: upneeq.com